New AJOVY® (fremanezumab) Migraine Prevention Data Challenges Treatment Pauses
Enforcement Report - Week of June 26, 2024
June 25 (Reuters) - Teva Pharmaceutical Industries (TEVA.TA), opens new tab has entered into a deal with the Israel Tax Authority to resolve all pending litigation related to taxes payable for the years from 2008 to 2020, the drugmaker said on Tuesday.
Teva Reaches Agreement With the Israel Tax Authority to Resolve All Pending Litigation for the Company's Taxable Years 2008-2020
Teva launches generic version of Novo Nordisk`s diabetes drug Victoza
Teva sues Corcept over mifepristone `monopoly` for rare disorder
The Department of Health – Abu Dhabi (DoH), the regulator of the healthcare sector, has signed a second Memorandum of Understanding (MoU) with the Perelman School of Medicine at the University of Pennsylvania (Penn Medicine), US to expand partnership in education, research and innovation programmes.
Teva Pharms's Generic Perampanel Receives Tentative Approval in US
Teva to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
New Data Provide Schizophrenia Treatment Insights into Switching to UZEDY® (risperidone) Extended-Release Injectable Suspension from Invega Sustenna® (paliperidone palmitate)